LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

  LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue
  Contingent Interest

Business Wire

BURLINGTON, N.C. -- March 11, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) announced
today that for the period of March 12, 2013 to September 11, 2013, its Zero
Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will,
subject to the terms of the Zero Coupon Notes, accrue contingent cash interest
at a rate of no less than 0.125% of the average market price of a Zero Coupon
Note for the five trading days ended March 6, 2013, in addition to the
continued accrual of the original issue discount. Contingent cash interest,
which the Company has determined to be approximately $1.49 per Note, will be
payable to holders of the Zero Coupon Notes as of the record date, which is
August 27, 2013. The payment of contingent cash interest is expected to be
made on September 11, 2013.

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its Specialty Testing Group:
The Center for Molecular Biology and Pathology, National Genetics Institute,
ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink
Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc,
Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox,
and Endocrine Sciences. LabCorp conducts clinical trials testing through its
LabCorp Clinical Trials division. LabCorp clients include physicians,
government agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our company, visit our Web site
at: www.labcorp.com.

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.

Contact:

Laboratory Corporation of America^® Holdings
Investor/Media Contact:
Stephen Anderson, 336-436-5076
www.labcorp.com